Press Release
Pisa, Italy – Decembre 2025
AIGEA Medical, a medical technology company focused on advanced solutions in breast screening and AI-driven diagnostics, announces that it has been granted a patent in the United States for its proprietary technology. This milestone complements the patent already granted in Italy and the ongoing process toward European patent protection.
The U.S. patent grant represents a strategic step in the company’s global growth strategy and reinforces the value of its intellectual property in one of the world’s most important healthcare and medtech markets.
Specifically, the U.S. patent:
- enhances the company’s attractiveness to international investors seeking strong and globally protected intellectual property;
- increases visibility and credibility within the U.S. clinical ecosystem, supporting collaborations and joint research and validation activities with leading medical centers;
- contributes to the overall increase in company valuation by strengthening its technological and competitive positioning;
- enables access to a broad and highly strategic market, expanding beyond the Italian and European contexts.
“This achievement marks another important milestone in our long-term development journey,” said Carlo Aliprandi, CEO. “It reflects years of research, technological development, and commitment, and positions the company for further growth, partnerships, and innovation on a global scale.”
